ADP-Ribosylation in Pathogens
ADP-ribosylation was discovered over 60 years ago, and much of the research focused on bacterial toxins that employed ADP-ribosylation to kill host cells. However, in the last 20 years, the field has identified many cases where host-mediated ADP-ribosylation can either promote or repress pathogenic...
Na minha lista:
| Formato: | Online |
|---|---|
| Idioma: | inglês |
| Publicado em: |
MDPI - Multidisciplinary Digital Publishing Institute
2024
|
| Assuntos: | |
| Acesso em linha: | ONIX_20240704_9783725809868_21 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
| _version_ | 1869517250522775552 |
|---|---|
| collection | Directory of Open Access Books |
| description | ADP-ribosylation was discovered over 60 years ago, and much of the research focused on bacterial toxins that employed ADP-ribosylation to kill host cells. However, in the last 20 years, the field has identified many cases where host-mediated ADP-ribosylation can either promote or repress pathogenic infections. It is clear that ADP-ribosylation is a key component of the innate immune response in eukaryotes and bacteria, and many of the mechanistic details of how ADP-ribosylation impacts pathogens have yet to be uncovered. In this Special Issue, we have focused on publishing unique reviews and primary research on the topics of pathogens and ADP-ribosylation. We hope that you will enjoy this collection. |
| format | Online |
| id | doab-20.500.12854ir-139225 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2024 |
| publishDateRange | 2024 |
| publishDateSort | 2024 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1392252024-07-04T09:29:31Z ADP-Ribosylation in Pathogens Leung, Anthony K L Fehr, Anthony Abraham, Rachy coronavirus alphavirus SARS-CoV-2 macrodomain ADP-ribosylation ADP-ribosylhydrolase therapeutics 14-3-3 activated bacterial exotoxins actin Aeromonas salmonicid protein refolding type III secretion system Pseudomonas aeruginosa toxin–antitoxin DarT/DarG DNA modification cell growth phage defence antimicrobial resistance PARylation MARylation post-translational modifications viral infection antiviral response IFN-I innate immunity COVID-19 non-structural protein 3 (NSP3) drug discovery and development virtual screening hydrolase interferon PARP RNA-virus Legionella pneumophila SidE family effector PR-ubiquitination host-pathogen interaction host–virus evolution phylogenetics alphaviruses coronaviruses PARG Trypanosoma Leishmania poly ADP-ribosylation Aedes aegypti tankyrase chikungunya virus (CHIKV) immunity mass spectrometry proteomics poly(ADP-ribose) glycohydrolase Diphtheria toxin-like ADP-ribosyltransferases chronic infection arboviruses cardiovascular disease emphysema alcoholic liver disease host–pathogen interactions Mac1 inhibitors PARP1 DNA virus epigenetic viral gene regulation thema EDItEUR::P Mathematics and Science thema EDItEUR::P Mathematics and Science::PS Biology, life sciences thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSG Microbiology (non-medical) thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKF Pathology::MKFM Medical microbiology and virology ADP-ribosylation was discovered over 60 years ago, and much of the research focused on bacterial toxins that employed ADP-ribosylation to kill host cells. However, in the last 20 years, the field has identified many cases where host-mediated ADP-ribosylation can either promote or repress pathogenic infections. It is clear that ADP-ribosylation is a key component of the innate immune response in eukaryotes and bacteria, and many of the mechanistic details of how ADP-ribosylation impacts pathogens have yet to be uncovered. In this Special Issue, we have focused on publishing unique reviews and primary research on the topics of pathogens and ADP-ribosylation. We hope that you will enjoy this collection. 2024-07-04T09:29:28Z 2024-07-04T09:29:28Z 2024 book ONIX_20240704_9783725809868_21 9783725809868 9783725809851 https://directory.doabooks.org/handle/20.500.12854/139225 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International https://mdpi.com/books/pdfview/book/9220 https://mdpi.com/books/pdfview/book/9220 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-7258-0985-1 10.3390/books978-3-7258-0985-1 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783725809868 9783725809851 222 open access |
| spellingShingle | coronavirus alphavirus SARS-CoV-2 macrodomain ADP-ribosylation ADP-ribosylhydrolase therapeutics 14-3-3 activated bacterial exotoxins actin Aeromonas salmonicid protein refolding type III secretion system Pseudomonas aeruginosa toxin–antitoxin DarT/DarG DNA modification cell growth phage defence antimicrobial resistance PARylation MARylation post-translational modifications viral infection antiviral response IFN-I innate immunity COVID-19 non-structural protein 3 (NSP3) drug discovery and development virtual screening hydrolase interferon PARP RNA-virus Legionella pneumophila SidE family effector PR-ubiquitination host-pathogen interaction host–virus evolution phylogenetics alphaviruses coronaviruses PARG Trypanosoma Leishmania poly ADP-ribosylation Aedes aegypti tankyrase chikungunya virus (CHIKV) immunity mass spectrometry proteomics poly(ADP-ribose) glycohydrolase Diphtheria toxin-like ADP-ribosyltransferases chronic infection arboviruses cardiovascular disease emphysema alcoholic liver disease host–pathogen interactions Mac1 inhibitors PARP1 DNA virus epigenetic viral gene regulation thema EDItEUR::P Mathematics and Science thema EDItEUR::P Mathematics and Science::PS Biology, life sciences thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSG Microbiology (non-medical) thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKF Pathology::MKFM Medical microbiology and virology ADP-Ribosylation in Pathogens |
| title | ADP-Ribosylation in Pathogens |
| title_full | ADP-Ribosylation in Pathogens |
| title_fullStr | ADP-Ribosylation in Pathogens |
| title_full_unstemmed | ADP-Ribosylation in Pathogens |
| title_short | ADP-Ribosylation in Pathogens |
| title_sort | adp ribosylation in pathogens |
| topic | coronavirus alphavirus SARS-CoV-2 macrodomain ADP-ribosylation ADP-ribosylhydrolase therapeutics 14-3-3 activated bacterial exotoxins actin Aeromonas salmonicid protein refolding type III secretion system Pseudomonas aeruginosa toxin–antitoxin DarT/DarG DNA modification cell growth phage defence antimicrobial resistance PARylation MARylation post-translational modifications viral infection antiviral response IFN-I innate immunity COVID-19 non-structural protein 3 (NSP3) drug discovery and development virtual screening hydrolase interferon PARP RNA-virus Legionella pneumophila SidE family effector PR-ubiquitination host-pathogen interaction host–virus evolution phylogenetics alphaviruses coronaviruses PARG Trypanosoma Leishmania poly ADP-ribosylation Aedes aegypti tankyrase chikungunya virus (CHIKV) immunity mass spectrometry proteomics poly(ADP-ribose) glycohydrolase Diphtheria toxin-like ADP-ribosyltransferases chronic infection arboviruses cardiovascular disease emphysema alcoholic liver disease host–pathogen interactions Mac1 inhibitors PARP1 DNA virus epigenetic viral gene regulation thema EDItEUR::P Mathematics and Science thema EDItEUR::P Mathematics and Science::PS Biology, life sciences thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSG Microbiology (non-medical) thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKF Pathology::MKFM Medical microbiology and virology |
| topic_facet | coronavirus alphavirus SARS-CoV-2 macrodomain ADP-ribosylation ADP-ribosylhydrolase therapeutics 14-3-3 activated bacterial exotoxins actin Aeromonas salmonicid protein refolding type III secretion system Pseudomonas aeruginosa toxin–antitoxin DarT/DarG DNA modification cell growth phage defence antimicrobial resistance PARylation MARylation post-translational modifications viral infection antiviral response IFN-I innate immunity COVID-19 non-structural protein 3 (NSP3) drug discovery and development virtual screening hydrolase interferon PARP RNA-virus Legionella pneumophila SidE family effector PR-ubiquitination host-pathogen interaction host–virus evolution phylogenetics alphaviruses coronaviruses PARG Trypanosoma Leishmania poly ADP-ribosylation Aedes aegypti tankyrase chikungunya virus (CHIKV) immunity mass spectrometry proteomics poly(ADP-ribose) glycohydrolase Diphtheria toxin-like ADP-ribosyltransferases chronic infection arboviruses cardiovascular disease emphysema alcoholic liver disease host–pathogen interactions Mac1 inhibitors PARP1 DNA virus epigenetic viral gene regulation thema EDItEUR::P Mathematics and Science thema EDItEUR::P Mathematics and Science::PS Biology, life sciences thema EDItEUR::P Mathematics and Science::PS Biology, life sciences::PSG Microbiology (non-medical) thema EDItEUR::M Medicine and Nursing::MK Medical specialties, branches of medicine::MKF Pathology::MKFM Medical microbiology and virology |
| url | ONIX_20240704_9783725809868_21 |